Comparison of the effects of flushing the graft with two different solutions before reperfusion on post-reperfusion complications and graft function in liver transplantation

Comparison of normal saline or hydroxyethylstarch solutions used for graft rinse prior to reperfusion on post reperfusion syndrome and postoperative graft function in human orthotopic liver transplantation

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121204011662N18

Enrollment

Registered

2025-07-19

Start date

2025-08-01

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver transplantation. Surgical operation with transplant of whole organ as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure

Interventions

Intervention 1: Intervention group: In this study, only livers sent from outside the city of Shiraz to Abu Ali Sina Hospital are included. During the liver transplantation surgery, before establishing

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: To standardize conditions, this study will be conducted only on livers sent from outside the city of Shiraz. Livers harvested within Bouali Hospital will not be included in this study. Adult patients over 18 years old. Adult patients who are candidate for Orthotopic liver transplantation

Exclusion criteria

Exclusion criteria: Macrosteatosis greater than 30% in the liver History of kidney failure and dialysis in the recipient History of heart failure with a cardiac output less than 30% in the recipient Second liver transplantation (re-transplantation) Incomplete completion of liver transplant surgery for any reason during the surgical procedure Discontinuation of hydroxyethyl starch production from the beginning of the Iranian year 1403 (2024-2025) and its removal from the national pharmacopeia

Design outcomes

Primary

Measure	Time frame
Central venous pressure. Timepoint: Immediately before re perfusion, as well as five and thirty minutes after completion of hepatic artery anastomosis. Method of measurement: Patient monitoring.;Blood pressure. Timepoint: Immediately before re perfusion, as well as five and thirty minutes after completion of hepatic artery anastomosis. Method of measurement: Patient monitoring.;Arterial blood gas parameters. Timepoint: Immediately before re perfusion, as well as five and thirty minutes after completion of hepatic artery anastomosis. Method of measurement: Blood test.	—

Measure

Time frame

Central venous pressure. Timepoint: Immediately before re perfusion, as well as five and thirty minutes after completion of hepatic artery anastomosis. Method of measurement: Patient monitoring.;Blood pressure. Timepoint: Immediately before re perfusion, as well as five and thirty minutes after completion of hepatic artery anastomosis. Method of measurement: Patient monitoring.;Arterial blood gas parameters. Timepoint: Immediately before re perfusion, as well as five and thirty minutes after completion of hepatic artery anastomosis. Method of measurement: Blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohsen Shirani

Shiraz University of Medical Sciences

mohsen_shirani@sums.ac.ir+98 71 1647 4270

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026